Product & Industry News
Native Antigen Company Antibody Conjugation Kits
The Native Antigen Company Introduces Antigen and Antibody Conjugation Kits

The Native Antigen Company Introduces Antigen and Antibody Conjugation Kits

Highly scalable kits enable researchers to prepare liquid-stable antigen and antibody conjugates with a wide range of labels including enzymes, fluorochromes, and biotin.

The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial release of its liquid format conjugation kits. The kits utilise a novel chemistry to generate highly reproducible antigen and antibody conjugates with a range of different labels, including enzymes, fluorochromes and biotin. The Native Antigen Company’s conjugation kits are multi-use, licence-free and fully scalable. These kits sit alongside the company’s existing portfolio of products to provide researchers with the opportunity to prepare stable conjugates, either from The Native Antigen Company’s extensive selection of viral and bacterial reagents or from their own in-house reagents.

The conjugation of antigens and antibodies to different enzymes and fluorochromes for use in immunoassays and other applications is often limited by the ability to prepare stable and reproducible conjugates. The Native Antigen Company’s conjugation kits provide a flexible solution that allows researchers to generate bespoke liquid-stable antigen and antibody conjugate formats for use in a broad range of research applications. Incorporation is highly efficient, helping to ensure lot-to-lot consistency, low backgrounds and improved assay sensitivity.

These easy-to-use kits are available with a range of different labels including alkaline phosphatase, horseradish peroxidase, fluorescein isothiocyanate, r-phycoerythrin and biotin, and include all of the reagents needed to conjugate proteins at optimal ratios. The liquid format requires no reconstitution and the kits are fully scalable from 0.01mg, to gram scale, meaning small scale trial conjugations can be rapidly developed into large scale conjugations.

Dr Andy Lane, Commercial Director, The Native Antigen Company, said: “The antigen and antibody conjugation kits are a valuable addition to The Native Antigen Company’s existing product range, and are complementary to our infectious disease offering that continues to provide vaccine and diagnostics researchers with a reliable source of high-quality reagents for immunoassay development and manufacturing. We are committed to building honest and transparent relationships with our customers who can purchase from us knowing that these systems are the same as those used internally for our own conjugations.”

The conjugation kits are provided licence-free for commercial use and The Native Antigen Company also provides custom conjugation of antigens and antibodies.

For more information about The Native Antigen Company’s antigen and antibody conjugation kits, please visit: https://thenativeantigencompany.com/conjugation-kits/